Sensitization Testing for Single-Use Medical Devices: Standards, Methods and Regulatory Compliance

Sensitization testing for single-use medical devices is a mandatory biocompatibility evaluation designed to determine whether device materials or their extracts can induce delayed-type hypersensitivity reactions in patients. Performed in accordance with ISO 10993-10 and ISO 10993-12, this testing is a core requirement for regulatory submissions to NMPA, FDA, and EU notified bodies. This article provides a comprehensive technical overview of sample preparation, test methods, applications, and frequently asked questions for sensitization testing of disposable medical devices.

Technical Overview

Sensitization testing, also referred to as delayed-type hypersensitivity testing, is a fundamental component of the biological safety evaluation required for single-use (disposable) medical devices. Because disposable devices such as infusion sets, catheters, syringes, gloves, and wound dressings make direct or indirect contact with skin, mucous membranes, or breached surfaces, chemical substances released from polymers, plasticizers, adhesives, colorants, processing aids, and sterilization residues (for example, ethylene oxide byproducts) may act as haptens and trigger immune-mediated sensitization upon repeated patient exposure.

The international standard ISO 10993-10 (Tests for irritation and skin sensitization), together with ISO 10993-1 (Evaluation and testing within a risk management process) and ISO 10993-12 (Sample preparation and reference materials), defines the framework for this evaluation. In China, the equivalent national standard GB/T 16886.10 applies and is referenced in NMPA product registration. The objective of the test is to characterize the skin sensitization potential of device extracts or materials so that risks can be controlled through material selection, design, labeling, and clinical use instructions.

Testing Samples

Polar and Non-Polar Device Extracts

For most disposable devices, testing is performed on extracts prepared according to ISO 10993-12. A polar medium (0.9% sodium chloride solution) and a non-polar medium (such as sesame oil or cottonseed oil) are used in parallel to capture both hydrophilic and lipophilic leachables. Typical extraction ratios include 3 cm²/mL for surface-area-based materials, 0.2 g/mL for irregular porous or polymeric solids, and 0.1 g/mL for liquids or gels. Standard extraction conditions include 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, selected to provide an exaggerated but non-degrading simulation of clinical exposure.

Cut Sections of Whole Devices

For devices intended for direct and prolonged skin contact, such as adhesive dressings, electrode patches, tubing supports, and fixation films, sections of the final sterilized product may be applied directly in patch-based methods. Testing the final product in its sterilized, ready-to-use condition ensures that sterilization residues and packaging interactions are captured in the evaluation.

Liquid Contacting Components and Process Residues

Liquid components delivered through the device, residual monomers, mold release agents, lubricious coatings, and sterilant residues may be evaluated as delivered, diluted, or concentrated depending on clinical exposure and analytical characterization data. Where substantial equivalence or extractables and leachables (E&L) data exist, a scientific justification may support reduced or targeted sensitization testing.

Testing Items

The sensitization evaluation for single-use medical devices typically includes the following test items, each documented with dose groups, controls, and scoring results:

• Delayed-type hypersensitivity potential of polar extracts of the final device
• Delayed-type hypersensitivity potential of non-polar extracts of the final device
• Skin sensitization potential of materials applied directly in patch form
• Sensitization evaluation following sterilization (including ethylene oxide residual considerations)
• Induction-phase and challenge-phase response scoring with Magnusson-Kligman grading (Grade 0 to Grade 3)
• Interpretation of response incidence and intensity versus negative and positive controls

Testing Methods

Guinea Pig Maximization Test (GPMT)

The Guinea Pig Maximization Test, based on the Magnusson-Kligman method, is the most widely accepted in vivo procedure for device extracts. It combines intradermal induction (with and without Freund's Complete Adjuvant), topical induction, a rest period, and a topical challenge approximately two weeks after induction. Challenge sites are graded at 24, 48, and 72 hours, and results are interpreted by comparing erythema and edema incidence between test and control animals. The GPMT is considered the most sensitive in vivo assay and is the default recommendation for devices with prolonged or mucosal contact.

Buehler Closed-Patch Test

The Buehler test uses repeated topical application without adjuvant and is appropriate for devices whose anticipated clinical exposure is limited to intact skin, such as gloves, drainage bags, external catheter fixation sets, and monitoring accessories. Induction is performed through occlusive patches over approximately two weeks, followed by a rest period and a challenge patch. This method is less sensitive than the GPMT but better reflects direct skin contact scenarios.

Murine Local Lymph Node Assay (LLNA)

The Local Lymph Node Assay measures lymphocyte proliferation in the draining auricular lymph nodes of mice after repeated topical exposure, quantified as a Stimulation Index (SI) relative to vehicle controls. Radioisotopic (tritiated thymidine) and non-radioactive (BrdU-ELISA) variants are available. An SI of 3 or greater indicates sensitization potential. The LLNA offers animal welfare advantages, shorter study duration, and dose-response information, and is well suited to soluble test articles and well-characterized materials.

In Vitro Alternative Methods

Aligned with the 3Rs principle (replacement, reduction, refinement), in vitro methods defined in OECD Test Guidelines 442C, 442D, and 442E, including the Direct Peptide Reactivity Assay (DPRA), KeratinoSens (ARE-Nrf2 keratinocyte activation), and h-CLAT or U-SENs (dendritic cell activation), may be deployed within defined Integrated Approaches to Testing and Assessment (IATA). The 2021 revision of ISO 10993-10 formally recognizes these methods, and their use for medical devices must be justified based on the applicability domain of the chemical space identified through material characterization.

Applications

Sensitization testing is applied throughout the product lifecycle of single-use medical devices:

• Regulatory registration and type testing for NMPA submission of Class II and Class III disposable devices in China
• Biological evaluation files supporting FDA 510(k) and PMA submissions in the United States
• CE marking technical documentation under the EU Medical Device Regulation (MDR) 2017/745
• Blood contact devices, including infusion sets, transfusion sets, dialyzers, and extracorporeal circuit tubing
• Topically applied disposables, such as surgical drapes, wound dressings, ostomy products, and electrode gels
• Evaluation after material supplier changes, formulation changes, manufacturing site transfers, or changes in the sterilization modality
• Root cause investigation and risk management support following adverse event reports of suspected allergic reactions

FAQ

Why is sensitization testing mandatory for single-use medical devices? Because disposable devices frequently contact skin, mucosa, or blood, and because sensitization is an irreversible immune memory response triggered by even low-level chemical exposure, ISO 10993-1 requires a sensitization endpoint for all external communication and external indirect communication devices unless a documented toxicological risk assessment justifies omission.

Which standards govern the test? ISO 10993-10 and its Chinese counterpart GB/T 16886.10 specify the sensitization methods, while ISO 10993-12 governs sample preparation and extraction. Test facilities should also be accredited under ISO/IEC 17025 and comply with GLP where applicable.

How should samples be submitted? Samples of the final product, in the final packaging and final sterilization condition, should be provided in a quantity sufficient for both polar and non-polar extraction, typically calculated from the device surface area or mass according to the extraction ratio. Unused, non-sterile prototypes are generally not acceptable for registration testing.

How long does testing take? The GPMT typically requires six to eight weeks including acclimatization, induction, rest, challenge, and reporting. The Buehler test and LLNA generally require four to six weeks, while in vitro methods can be completed within two to four weeks.

Can in vitro tests replace animal testing? In vitro methods may replace animal assays when the chemical characterization of the device demonstrates that its leachables fall within the applicability domain of the chosen in vitro test battery and a defined approach justification is documented in the biological evaluation report, subject to acceptance by the relevant regulatory authority.

What results indicate a pass? A device is generally considered acceptable when the incidence and intensity of challenge reactions in test animals are not greater than those in negative controls and are within the response ranges observed for recognized reference materials. Positive findings require a risk-benefit analysis, material substitution, process optimization, or labeling controls such as contraindications and warning statements.